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Fetuin-A is a liver secretory
glycoprotein that has been linked to
the development of insulin resistance
in animal models (1). Recent work
suggests that free fatty acids (FFAs)
and fetuin-A interact to induce insulin
resistance in animal models (1) and
humans (2). However, short-term
overfeeding increases peripheral
insulin resistance without significant
increases in the levels of circulating
FFAs in healthy humans (3,4). Thus,
short-term overfeeding studies provide
an ideal model with which to evaluate
the relationships between fetuin-A and
insulin resistance, independent of
FFAs.
We examined the effects of 28-day
overfeeding (1,100 6 100 kcal/day
above baseline energy requirement,
increasing mean [6SEM] dietary fat
intake from 34 6 1% to 45 6 1% of
energy intake) on circulating levels of
fetuin-A, FFAs, and proinflammatory
markers in healthy men and women
(BMI 25.6 6 0.6; age 37 6 2 years;
n 5 40 [20 men]). The study protocol
was described in detail previously (3)
and approved by the Human Research
and Ethics Committee at St. Vincent’s
Hospital (Sydney, New South Wales,
Australia). Metabolic studies were
performed at baseline and after 28-day
overfeeding, and included 2-h
euglycemic (5 mmol/L)
hyperinsulinemic (60 mU/m2) clamp to
evaluate insulin sensitivity, dual-
energy X-ray absorptiometry (Lunar
DPX; Lunar Corp., Madison, WI) to
evaluate body fat composition, and
computed tomography (Gemini GXL;
Phillips) to evaluate abdominal fat
distribution and liver density. Fasting
circulating concentrations of fetuin-A
(BioVendor, Brno, Czech Republic),
FFAs (Wako, Osaka, Japan), monocyte
chemoattractant protein-1 (MCP-1;
R&D Systems, Minneapolis, MN), and
high-sensitivity C-reactive protein
(CRP; Beckman Coulter Inc., Sydney,
New South Wales, Australia) were
also measured at baseline and in
response to overfeeding. Statistical
analyses included repeated-measures
ANOVA to evaluate the change in end
points with overfeeding and linear
regression models to evaluate the
relationships among variables,
with age and sex as independent
variables.
Weight, body fat mass, and visceral and
subcutaneous abdominal adipose tissue
increased, whereas liver density
(inversely proportional to liver fat)
decreased (Fig. 1). The glucose infusion
rate necessary to maintain euglycemia
during the hyperinsulinemic clamp
decreased, and the homeostasis model
assessment of insulin resistance
increased, indicating reduced insulin
sensitivity with overfeeding (Fig. 1).
Circulating levels of fetuin-A and the
inflammatory markers CRP and MCP-1
were all increased with overfeeding (Fig.
1). Consistent with other short-term
overfeeding studies in healthy
individuals (4), fasting FFA levels were
not elevated (P5 0.4; Fig. 1). Moreover,
the insulin sensitivity response to
overfeeding was not explained by FFA
response (b520.15, P5 0.9), fetuin-A
response (b520.08, P5 0.9), or their
interaction (b 5 20.09, P 5 0.9).
Interestingly, baseline circulating levels
of fetuin-A were correlated with those
ofMCP-1 (b5 0.36, P5 0.04), andMCP-
1 response to overfeeding was
explained by fetuin-A response (b 5
0.39, P 5 0.02), demonstrating a link
between fetuin-A and low-grade
inflammation in healthy humans.
In conclusion, opposite to findings
concerning caloric restriction and
weight loss (5), caloric excess and
weight gain resulted in significant
elevations in circulating levels of
fetuin-A in humans. Relationships
between fetuin-A and MCP-1 provide
support for the notion that fetuin-A
may be involved in an inflammatory
response. However, our study suggests
that this may have occurred
1Diabetes and Obesity Program, Garvan Institute of Medical Research, New South Wales, Australia
2Faculty of Medicine, University of New South Wales, New South Wales, Australia
3The Charles Perkins Centre and School of Biological Sciences, University of Sydney, New South Wales, Australia
4Discipline of Medicine, University of Adelaide, South Australia, Australia
Corresponding author: Dorit Samocha-Bonet, d.samochabonet@garvan.org.au.




and Leonie Kaye Heilbronn4












independent of FFA, although detailed
studies of fatty acid utilization were
not performed. Further study is
needed to elucidate the role of
fetuin-A in weight gain–associated
insulin resistance in humans.
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2. Stefan N, Häring HU. Circulating fetuin-A and
free fatty acids interact to predict insulin
resistance in humans. Nat Med 2013;19:
394–395
3. Samocha-Bonet D, Campbell LV,Mori TA, et al.
Overfeeding reduces insulin sensitivity and
increases oxidative stress, without altering
markers of mitochondrial content and
function in humans. PLoS One 2012;7:
e36320
4. Brøns C, Jensen CB, Storgaard H, et al.
Impact of short-term high-fat feeding on
glucose and insulin metabolism in young
healthy men. J Physiol 2009;587:2387–
2397
5. Choi KM, Han KA, Ahn HJ, et al. The
effects of caloric restriction on fetuin-A
and cardiovascular risk factors in rats
and humans: a randomized controlled
trial. Clin Endocrinol (Oxf) 2013;79:356–
363
Figure 1—Effects of 28-day overfeeding on BMI, fat distribution, insulin sensitivity, and
circulating levels of proinflammatory markers, FFAs, and fetuin-A in healthy humans. Data are
the mean fold change 6 SEM (n 5 40; 20 men/20 women). *P , 0.05, **P , 0.01, compared
with baseline levels by repeated-measures ANOVA. CRP, MCP-1, FFA, and fetuin-A data were
log-transformed prior to statistical analysis. AT, adipose tissue (at the L4/L5 disc space); HOMA-
IR, homeostasis model assessment of insulin resistance; hs-CRP, high-sensitivity CRP.
e16 Overfeeding and Circulating Fetuin-A Diabetes Care Volume 37, January 2014
